"For children who have had HIV-1 infection since birth, the combination drug therapies now used to treat HIV appear to protect against the heart damage seen before combination therapies were available, according to researchers in a National Instit"...
DOSAGE AND ADMINISTRATION
The recommended dose of FULYZAQ is one 125 mg delayed-release tablet taken orally two times a day, with or without food. FULYZAQ tablets should not be crushed or chewed. Tablets should be swallowed whole.
Dosage Forms And Strengths
FULYZAQ is a white, oval, enteric-coated 125 mg delayed-release tablet printed on one side with 125SLXP.
Storage And Handling
Crofelemer delayed-release tablets, 125 mg, are white, oval enteric-coated tablets printed on one side with 125SLXP. They are available in the following package size:
Bottles of 60: NDC 65649-802-02
Store at 20°C-25°C (68°F-77°F); excursions permitted between 15°C-30°C (59°F-86°F). See USP Controlled Room Temperature.
Manufactured for Salix Pharmaceuticals, Inc., Raleigh, NC 27615 by Patheon, Inc. FULYZAQ is distributed by Salix Pharmaceuticals, Inc. under license from Napo Pharmaceuticals, Inc. Revised: 12/31/2012
Last reviewed on RxList: 1/10/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Fulyzaq Information
Report Problems to the Food and Drug Administration
Get breaking medical news.